Carter Gould
Stock Analyst at Cantor Fitzgerald
(1)
# 2122
Out of 5,352 analysts
223
Total ratings
42.61%
Success rate
0.20%
Average return
Main Sectors:
| Name | Action | PT | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
VRTX Vertex Pharmaceutica... | Reiterates: Overweight | 535 535 | 446.46 | 19.83% | 3 | May 6, 2025 | |
BMY Bristol-Myers Squibb | Reiterates: Neutral | 55 55 | 48.1 | 14.35% | 16 | Apr 23, 2025 | |
REGN Regeneron Pharmaceut... | Assumes: Overweight | 695 | 487.82 | 42.47% | 19 | Apr 22, 2025 | |
PFE Pfizer | Initiates Coverage On: Neutral | 24 | 23.36 | 2.74% | 15 | Apr 22, 2025 | |
PCVX Vaxcyte | Initiates Coverage On: Overweight | n/a | n/a | n/a | 1 | Apr 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Neutral | 85 | 77.06 | 10.3% | 11 | Apr 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 975 | 750.81 | 29.86% | 12 | Apr 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Assumes: Overweight | 125 | 109.4 | 14.26% | 15 | Apr 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 210 | 187.14 | 12.22% | 15 | Apr 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 160 165 | 125.02 | 31.98% | 12 | Dec 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 18 20 | 15.39 | 29.95% | 6 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 190 180 | 131.85 | 36.52% | 24 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 300 315 | 289.7 | 8.73% | 16 | Oct 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 100 | 78.17 | 27.93% | 1 | Aug 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 10 3 | 0.22 | 1263.64% | 4 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 7 3 | 1.08 | 177.78% | 1 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 9 | 1.57 | 473.25% | 1 | Jun 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 100 95 | 32.02 | 196.69% | 2 | May 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 25 20 | 19.37 | 3.25% | 5 | Apr 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 62 73 | 65.17 | 12.01% | 4 | Feb 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Underweight | 2 1 | n/a | n/a | 4 | Jan 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Equal-Weight | 110 172 | n/a | n/a | 7 | Aug 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 14 12 | 1.48 | 710.81% | 4 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 2 2 | 1.22 | 22.95% | 6 | Mar 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 68 15 | n/a | n/a | 3 | Nov 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 3 3 | 0.35 | 542.86% | 4 | Aug 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 392 380 | 263.9 | 43.99% | 1 | Jan 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Equal-Weight | 150 180 | n/a | n/a | 4 | Oct 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | n/a | n/a | n/a | 4 | Apr 1, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 75 82 | 67.09 | 22.22% | 3 | Jan 16, 2019 |